{"ID": "DDI-DrugBank.d31.s1.p1", "TEXT1": "When other potent parental @DRUG$, such as diazoxide, are used in combination with @DRUG$, patients should be continuously observed for several hours for any excessive fall in blood pressure.", "LBL": "DDI-effect", "DRUGA": ["antihypertensive drugs", "group", "27-48"], "DRUGB": ["hydralazine", "drug", "99-109"]}
{"ID": "DDI-MedLine.d57.s1.p2", "TEXT1": "The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed @DRUG$ and some are @DRUG$ as well.", "LBL": "0", "DRUGA": ["analgesic agents", "group", "111-126"], "DRUGB": ["analgesic adjuvants", "group", "141-159"]}
{"ID": "DDI-DrugBank.d75.s4.p0", "TEXT1": "An in vivo interaction study in humans demonstrated that a single 1mg dose of @DRUG$ administered concomitantly with a single 900 mg dose of @DRUG$ was generally well tolerated.", "LBL": "0", "DRUGA": ["anagrelide", "drug", "78-87"], "DRUGB": ["aspirin", "brand", "145-151"]}
{"ID": "DDI-DrugBank.d167.s2.p21", "TEXT1": "In addition, neuromuscular blocking action is enhanced by general anesthetics, local anesthetics like lidocaine, @DRUG$, beta-blockers, metaclopramide, lithium carbonate, and @DRUG$.", "LBL": "0", "DRUGA": ["procaine", "drug", "113-120"], "DRUGB": ["terbutaline", "drug", "177-187"]}
{"ID": "DDI-DrugBank.d141.s7.p4", "TEXT1": "DIGOXIN: Plasma @DRUG$ levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.", "LBL": "0", "DRUGA": ["digoxin", "drug", "16-22"], "DRUGB": ["cerivastatin sodium", "drug", "118-136"]}
{"ID": "DDI-DrugBank.d236.s27.p1", "TEXT1": "@DRUG$: In cases of propoxyphene overdosage, @DRUG$ CNS stimulation is potentiated and fatal convulsions can occur.", "LBL": "0", "DRUGA": ["Propoxyphene", "drug", "0-11"], "DRUGB": ["amphetamine", "group", "51-61"]}
{"ID": "DDI-DrugBank.d367.s13.p0", "TEXT1": "@DRUG$ (e.g., @DRUG$).", "LBL": "0", "DRUGA": ["Antihistamines", "group", "0-13"], "DRUGB": ["chlorpheniramine", "group", "22-37"]}
{"ID": "DDI-MedLine.d69.s0.p1", "TEXT1": "Differential regulation of tyrosine phosphorylation in tumor cells by @DRUG$, a homodimeric disintegrin, and monomeric disintegrins echistatin and @DRUG$.", "LBL": "0", "DRUGA": ["contortrostatin", "drug_n", "70-84"], "DRUGB": ["flavoridin", "drug_n", "156-165"]}
{"ID": "DDI-DrugBank.d29.s13.p9", "TEXT1": "Coadministration of oral contraceptives, diazepam, phenytoin, or @DRUG$ did not seem to change the pharmacokinetic profile of @DRUG$.", "LBL": "0", "DRUGA": ["quinidine", "drug", "65-73"], "DRUGB": ["esomeprazole", "drug", "129-140"]}
{"ID": "DDI-DrugBank.d71.s3.p1", "TEXT1": "There is no information regarding the effect on @DRUG$ pharmacokinetics of higher doses of TMP/@DRUG$ such as those used to treat Pneumocystis carinii pneumonia.", "LBL": "0", "DRUGA": ["lamivudine", "drug", "48-57"], "DRUGB": ["SMX", "drug", "99-101"]}
{"ID": "DDI-DrugBank.d81.s7.p5", "TEXT1": "Cimetidine: In a study in healthy volunteers, a one-week course of cimetidine at 400 mg b.i.d. with a single 5 mg dose of @DRUG$ on the sixth day showed an increase in @DRUG$ mean peak plasma concentrations (36%) and significant increase in area under the curve (50%).", "LBL": "0", "DRUGA": ["isradipine", "drug", "122-131"], "DRUGB": ["isradipine", "drug", "172-181"]}
{"ID": "DDI-MedLine.d76.s1.p10", "TEXT1": "The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (@DRUG$) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (@DRUG$) and model peptide drugs, bacitracin and insulin.", "LBL": "0", "DRUGA": ["NaCMC", "drug_n", "87-91"], "DRUGB": ["NaFlu", "drug", "203-207"]}
{"ID": "DDI-DrugBank.d68.s4.p2", "TEXT1": "Calcium channel blocking agents: Coadministration of @DRUG$ did not have any effect on either the safety or efficacy of @DRUG$ in the clinical trials.", "LBL": "0", "DRUGA": ["calcium channel blockers", "group", "53-76"], "DRUGB": ["ibutilide", "drug", "138-146"]}
{"ID": "DDI-DrugBank.d485.s17.p26", "TEXT1": "Benzodiazepines: Combination hormonal contraceptives may decrease the clearance of some benzodiazepines (alprazolam, @DRUG$, @DRUG$) and increase the clearance of others (lorazepam, oxazepam, temazepam).", "LBL": "0", "DRUGA": ["chlordiazepoxide", "drug", "117-132"], "DRUGB": ["diazepam", "drug", "135-142"]}
{"ID": "DDI-DrugBank.d94.s11.p305", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, @DRUG$, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, @DRUG$, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["clobazam", "drug", "233-240"], "DRUGB": ["glucocorticoids", "group", "376-390"]}
{"ID": "DDI-DrugBank.d313.s1.p38", "TEXT1": "The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.", "LBL": "0", "DRUGA": ["fluoxetine", "drug", "197-206"], "DRUGB": ["octreotide", "drug", "299-308"]}
{"ID": "DDI-DrugBank.d304.s0.p4", "TEXT1": "May interact with the following: cholestyramine, @DRUG$ (use with thiazide diuretics may prevent the @DRUG$ from working properly;", "LBL": "0", "DRUGA": ["colestipol", "drug", "49-58"], "DRUGB": ["diuretic", "group", "105-112"]}
{"ID": "DDI-DrugBank.d3.s4.p23", "TEXT1": "Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, @DRUG$, acetaminophen, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.", "LBL": "0", "DRUGA": ["piroxicam", "drug", "70-78"], "DRUGB": ["phenytoin", "drug", "96-104"]}
{"ID": "DDI-DrugBank.d62.s0.p18", "TEXT1": "Dexbrompheniramine can interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).", "LBL": "0", "DRUGA": ["CNS depressants", "group", "54-68"], "DRUGB": ["monoamine oxidase (MAO) inhibitors", "group", "344-377"]}
{"ID": "DDI-DrugBank.d460.s11.p5", "TEXT1": "In vitro displacement studies with highly protein-bound drugs such as @DRUG$, propranolol, captopril, nicardipine, pravastatin, glyburide, @DRUG$, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.", "LBL": "0", "DRUGA": ["furosemide", "drug", "70-79"], "DRUGB": ["warfarin", "drug", "143-150"]}
{"ID": "DDI-DrugBank.d143.s28.p5", "TEXT1": "There have been case reports of increased steady-state levels of quinidine, procainamide, and @DRUG$ during concomitant therapy with @DRUG$.", "LBL": "0", "DRUGA": ["phenytoin", "drug", "94-102"], "DRUGB": ["amiodarone", "drug", "136-145"]}
{"ID": "DDI-DrugBank.d54.s8.p2", "TEXT1": "@DRUG$: Cholestyramine binds both T4 and @DRUG$ in the intestine, thus impairing absorption of these thyroid hormones.", "LBL": "0", "DRUGA": ["Cholestyramine", "drug", "0-13"], "DRUGB": ["T3", "drug", "49-50"]}
{"ID": "DDI-DrugBank.d187.s14.p2", "TEXT1": "Plasma @DRUG$ concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of @DRUG$ should be made.", "LBL": "0", "DRUGA": ["valproate", "drug", "7-15"], "DRUGB": ["valproate", "drug", "139-147"]}
{"ID": "DDI-DrugBank.d288.s1.p2", "TEXT1": "Pharmacokinetic data from these patients demonstrated a decrease in paclitaxel clearance of approximately 33% when @DRUG$ was administered following @DRUG$.", "LBL": "DDI-mechanism", "DRUGA": ["TAXOL", "brand", "115-119"], "DRUGB": ["cisplatin", "drug", "148-156"]}
{"ID": "DDI-DrugBank.d536.s1.p26", "TEXT1": "These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel-blocking drugs, and isoniazid.", "LBL": "0", "DRUGA": ["corticosteroids", "group", "55-69"], "DRUGB": ["nicotinic acid", "drug", "149-162"]}
{"ID": "DDI-DrugBank.d459.s1.p2", "TEXT1": "Caution should be taken when @DRUG$ is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and @DRUG$ (see CLINICAL PHARMACOLOGY).", "LBL": "DDI-advise", "DRUGA": ["ENABLEX", "brand", "29-35"], "DRUGB": ["tricyclic antidepressants", "group", "202-226"]}
{"ID": "DDI-DrugBank.d64.s87.p45", "TEXT1": "Drugs that reportedly may increase oral @DRUG$ response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;@DRUG$;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "DDI-effect", "DRUGA": ["anticoagulant", "group", "40-52"], "DRUGB": ["sulfinpyrazone", "drug", "817-830"]}
{"ID": "DDI-DrugBank.d86.s1.p38", "TEXT1": "Interactions may also occur with the following: anti-depressants/anti-anxiety drugs, drugs used to treat an overactive thyroid, @DRUG$ (e.g., propranolol), sparfloxacin, grepafloxacin, guanethidine, guanadrel, metrizamide, cabergoline, lithium, narcotic pain medication (e.g., codeine), drugs used to aid sleep, drowsiness-causing antihistamines (e.g., @DRUG$), any other drugs that may make you drowsy.", "LBL": "0", "DRUGA": ["beta-blockers", "group", "128-140"], "DRUGB": ["diphenhydramine", "drug", "360-374"]}
{"ID": "DDI-DrugBank.d455.s10.p9", "TEXT1": "These include probenecid, cholestyramine, and some @DRUG$ (e.g. @DRUG$, rifamipicin, ampicillin and chloramphenicol).", "LBL": "0", "DRUGA": ["antibiotics", "group", "51-61"], "DRUGB": ["erythromycin", "drug", "69-80"]}
{"ID": "DDI-DrugBank.d521.s2.p52", "TEXT1": "- a nonsteroidal anti-inflammatory drug (NSAID) such as @DRUG$ (Motrin, Advil, Nuprin, others), ketoprofen (Orudis, @DRUG$, Oruvail), diclofenac (Voltaren, Cataflam), etodolac (Lodine), indomethacin (Indocin), nabumetone (Relafen), oxaprozin (Daypro), and naproxen (Anaprox, Naprosyn, Aleve);", "LBL": "0", "DRUGA": ["ibuprofen", "drug", "56-64"], "DRUGB": ["Orudis KT", "brand", "119-127"]}
{"ID": "DDI-DrugBank.d482.s14.p147", "TEXT1": "Tell your doctor if you are taking any of the following drugs: blood thinners (Coumadin) other antidepressants metoprolol antihistamines carbamazepine (Tegretol) cimetidine (Tagamet) estrogens fluoxetine (Prozac) intraconazole (Sporanox) ketoconazole (@DRUG$) @DRUG$ lithium muscle relaxants birth control pills sleeping pills thyroid medications", "LBL": "0", "DRUGA": ["Nizoral", "brand", "252-258"], "DRUGB": ["levodopa", "drug", "261-268"]}
{"ID": "DDI-DrugBank.d124.s26.p105", "TEXT1": "Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;", "LBL": "0", "DRUGA": ["cyclosporine", "drug", "225-236"], "DRUGB": ["alprazolam", "drug", "305-314"]}
{"ID": "DDI-DrugBank.d379.s1.p5", "TEXT1": "It is, however, possible that concomitant use of other known @DRUG$ such as griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides and @DRUG$ might increase the photosensitivity reaction of actinic keratoses treated with the LEVULAN KERASTICK for Topical Solution.", "LBL": "0", "DRUGA": ["photosensitizing agents", "group", "61-83"], "DRUGB": ["tetracyclines", "group", "175-187"]}
{"ID": "DDI-DrugBank.d209.s3.p17", "TEXT1": "Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.", "LBL": "0", "DRUGA": ["acetaminophen", "drug", "167-179"], "DRUGB": ["angiotensin-converting enzyme (ACE) inhibitors", "group", "228-273"]}
{"ID": "DDI-DrugBank.d0.s0.p5", "TEXT1": "The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either @DRUG$ or @DRUG$.", "LBL": "0", "DRUGA": ["alcohol", "drug", "97-103"], "DRUGB": ["acamprosate", "drug", "108-118"]}
{"ID": "DDI-DrugBank.d568.s17.p11", "TEXT1": "If concomitant treatment with sumatriptan and an @DRUG$ (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, @DRUG$, escitalopram) is clinically warranted, appropriate observation of the patient is advised.", "LBL": "0", "DRUGA": ["SSRI", "group", "49-52"], "DRUGB": ["citalopram", "drug", "110-119"]}
{"ID": "DDI-DrugBank.d455.s10.p5", "TEXT1": "These include probenecid, @DRUG$, and some @DRUG$ (e.g. erythromycin, rifamipicin, ampicillin and chloramphenicol).", "LBL": "0", "DRUGA": ["cholestyramine", "drug", "26-39"], "DRUGB": ["antibiotics", "group", "51-61"]}
{"ID": "DDI-DrugBank.d420.s0.p0", "TEXT1": "@DRUG$ (@DRUG$- or magnesium-containing): Concomitant administration of 300-mg cefdinir capsules with 30 mL Maalox TC suspension reduces the rate (Cmax) and extent (AUC) of absorption by approximately 40%.", "LBL": "0", "DRUGA": ["Antacids", "group", "0-7"], "DRUGB": ["aluminum", "drug", "10-17"]}
{"ID": "DDI-DrugBank.d115.s0.p13", "TEXT1": "Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).", "LBL": "DDI-advise", "DRUGA": ["Gleevec", "brand", "150-156"], "DRUGB": ["erythromycin", "drug", "230-241"]}
{"ID": "DDI-DrugBank.d484.s0.p978", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), @DRUG$ (rifampin), St. Johns wort, temazepam, theophylline (@DRUG$), and vitamin C.", "LBL": "0", "DRUGA": ["rifadin", "brand", "538-544"], "DRUGB": ["Theo-Dur", "brand", "599-606"]}
{"ID": "DDI-DrugBank.d561.s10.p35", "TEXT1": "Other No clinically important pharmacokinetic interactions occurred when Lotensin was administered concomitantly with hydrochlorothiazide, chlorthalidone, furosemide, digoxin, propranolol, atenolol, @DRUG$, or @DRUG$.", "LBL": "0", "DRUGA": ["naproxen", "drug", "199-206"], "DRUGB": ["cimetidine", "drug", "212-221"]}
{"ID": "DDI-DrugBank.d170.s5.p38", "TEXT1": "Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.", "LBL": "0", "DRUGA": ["central nervous system depressants", "group", "111-144"], "DRUGB": ["anesthetics", "group", "260-270"]}
{"ID": "DDI-DrugBank.d291.s0.p2", "TEXT1": "When @DRUG$ or Bezalip retard is used at the same time as other medicines or substances the following interactions must be taken into account: - Bezalip and @DRUG$ may enhance the action of anticoagulants of the coumarin type.", "LBL": "0", "DRUGA": ["Bezalip", "brand", "5-11"], "DRUGB": ["Bezalip retard", "brand", "158-171"]}
{"ID": "DDI-MedLine.d15.s0.p12", "TEXT1": "[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of @DRUG$ binding after the long-term administration of neuroleptics] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for @DRUG$ in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain.", "LBL": "0", "DRUGA": ["3H-spiroperidol", "drug_n", "75-89"], "DRUGB": ["apomorphine", "drug", "418-428"]}
{"ID": "DDI-DrugBank.d411.s4.p349", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, perchlorate, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, @DRUG$ and dopamine agonists, ethionamide, glucocorticoids, heparin, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, @DRUG$, thiazide diuretics.", "LBL": "0", "DRUGA": ["dopamine", "drug", "472-479"], "DRUGB": ["sulfonylureas", "group", "814-826"]}
{"ID": "DDI-DrugBank.d208.s0.p28", "TEXT1": "Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.", "LBL": "0", "DRUGA": ["lithium", "drug", "129-135"], "DRUGB": ["Aleve", "brand", "166-170"]}
{"ID": "DDI-DrugBank.d484.s0.p505", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), @DRUG$ (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (@DRUG$, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["antifungals", "group", "215-225"], "DRUGB": ["Agenerase", "brand", "386-394"]}
{"ID": "DDI-DrugBank.d411.s4.p165", "TEXT1": "Thyroid Physiology: The following agents may alter thyroid hormone or TSH levels, generally by effects on thyroid hormone synthesis, secretion, distribution, metabolism, hormone action, or elimination, or altered TSH secretion: aminoglutethimide, p-aminosalicylic acid, amiodarone, androgens and related anabolic hormones, complex anions (thiocyanate, @DRUG$, pertechnetate), antithyroid drugs, b-adrenergic blocking agents, carbamazepine, chloral hydrate, diazepam, dopamine and dopamine agonists, ethionamide, glucocorticoids, @DRUG$, hepatic enzyme inducers, insulin, iodinated cholestographic agents, iodine-containing compounds, levodopa, lovastatin, lithium, 6-mercaptopurine, metoclopramide, mitotane, nitroprusside, phenobarbital, phenytoin, resorcinol, rifampin, somatostatin analogs, sulfonamides, sulfonylureas, thiazide diuretics.", "LBL": "0", "DRUGA": ["perchlorate", "drug", "352-362"], "DRUGB": ["heparin", "drug", "534-540"]}
{"ID": "DDI-DrugBank.d176.s12.p47", "TEXT1": "In separate single or multiple dose pharmacokinetic interaction studies with chlorthalidone, nifedipine, propanolol, hydrochlorothiazide, cimetidine, metoclopramide, @DRUG$, digoxin, and warfarin, the bioavailability of @DRUG$ was not altered by coadministration of fosinopril with any one of these drugs.", "LBL": "0", "DRUGA": ["propantheline", "drug", "166-178"], "DRUGB": ["fosinoprilat", "drug_n", "227-238"]}
{"ID": "DDI-DrugBank.d94.s11.p64", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: @DRUG$, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, @DRUG$, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["Acetaminophen", "drug", "157-169"], "DRUGB": ["itraconazole", "drug", "406-417"]}
{"ID": "DDI-DrugBank.d87.s18.p1", "TEXT1": "There has been little experience with the coadministration of @DRUG$ and either disopyramide or @DRUG$.", "LBL": "0", "DRUGA": ["TAMBOCOR", "brand", "62-69"], "DRUGB": ["verapamil", "drug", "98-106"]}
{"ID": "DDI-DrugBank.d76.s12.p11", "TEXT1": "Other Potentially Important Drug Interactions: Benzodiazepines: Benzodiazepines metabolized by hepatic oxidation (e.g., @DRUG$, midazolam, triazolam elc.) should be used with caution because the clearance of these drugs is likely to be reduced by @DRUG$.", "LBL": "DDI-mechanism", "DRUGA": ["alprazolam", "drug", "120-129"], "DRUGB": ["fluvoxamine", "drug", "251-261"]}
{"ID": "DDI-DrugBank.d568.s35.p3", "TEXT1": "Metoprolol - Administration of 20 mg/day @DRUG$ for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the @DRUG$ metoprolol (given in a single dose of 100 mg).", "LBL": "0", "DRUGA": ["LEXAPRO", "brand", "41-47"], "DRUGB": ["beta-adrenergic blocker", "group", "149-171"]}
{"ID": "DDI-DrugBank.d395.s22.p1", "TEXT1": "@DRUG$-related adverse effects have occurred in patients when theophylline and @DRUG$ were coadministered.", "LBL": "0", "DRUGA": ["Theophylline", "drug", "0-11"], "DRUGB": ["enoxacin", "drug", "85-92"]}
{"ID": "DDI-DrugBank.d94.s11.p846", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, @DRUG$, mirtazapine, @DRUG$, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["midazolam", "drug", "470-478"], "DRUGB": ["nortriptyline", "drug", "494-506"]}
{"ID": "DDI-DrugBank.d94.s11.p465", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, @DRUG$, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, @DRUG$, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["delavirdine", "drug", "279-289"], "DRUGB": ["theophylline", "drug", "634-645"]}
{"ID": "DDI-DrugBank.d478.s4.p14", "TEXT1": "Selective serotonin reuptake inhibitors (SSRIs) (e.g., fluoxetine, fluvoxamine, @DRUG$, @DRUG$) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HTv agonists.", "LBL": "0", "DRUGA": ["paroxetine", "drug", "80-89"], "DRUGB": ["sertraline", "drug", "92-101"]}
{"ID": "DDI-DrugBank.d460.s9.p2", "TEXT1": "Diclofenac: Administration of morning and lunch doses of @DRUG$ 120 mg in combination with a single 75-mg dose of @DRUG$ in healthy volunteers resulted in no significant changes to the pharmacokinetics of either agent.", "LBL": "0", "DRUGA": ["Starlix", "brand", "57-63"], "DRUGB": ["diclofenac", "drug", "115-124"]}
{"ID": "DDI-DrugBank.d237.s7.p3", "TEXT1": "@DRUG$: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.", "LBL": "0", "DRUGA": ["Antifungals", "group", "0-10"], "DRUGB": ["cisapride", "drug", "140-148"]}
{"ID": "DDI-DrugBank.d238.s4.p7", "TEXT1": "Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, @DRUG$, or similar agents, and such an effect may be anticipated with @DRUG$ because of its structural similarity to other tricyclic antidepressants.", "LBL": "0", "DRUGA": ["clonidine", "drug", "105-113"], "DRUGB": ["CMI", "drug", "178-180"]}
{"ID": "DDI-DrugBank.d94.s11.p169", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, @DRUG$, valproate, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["amitriptyline", "drug", "184-196"], "DRUGB": ["triazolam", "drug", "681-689"]}
{"ID": "DDI-DrugBank.d171.s0.p31", "TEXT1": "Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.", "LBL": "0", "DRUGA": ["propranolol", "drug", "171-181"], "DRUGB": ["lidocaine", "drug", "259-267"]}
{"ID": "DDI-MedLine.d84.s3.p8", "TEXT1": "To investigate the effects of antimicrobial combinations of GL with four kinds of @DRUG$ (ampicillin, cefazolin, oxytetracycline and @DRUG$), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain.", "LBL": "0", "DRUGA": ["antibiotics", "group", "82-92"], "DRUGB": ["chloramphenicol", "drug", "138-152"]}
{"ID": "DDI-MedLine.d30.s8.p4", "TEXT1": "In monkeys, the effects of (-)-NANM, but not @DRUG$ or PCP, were antagonized by @DRUG$;", "LBL": "0", "DRUGA": ["(+)-NANM", "drug_n", "45-52"], "DRUGB": ["naloxone", "drug", "82-89"]}
{"ID": "DDI-DrugBank.d396.s2.p4", "TEXT1": "The use of MAO inhibitors or @DRUG$ with @DRUG$ preparations may increase the effect of either the antidepressant or hydrocodone.", "LBL": "DDI-effect", "DRUGA": ["tricyclic antidepressants", "group", "29-53"], "DRUGB": ["hydrocodone", "drug", "60-70"]}
{"ID": "DDI-DrugBank.d338.s6.p2", "TEXT1": "Consequently, estazolam should be avoided in patients receiving @DRUG$ and @DRUG$, which are very potent inhibitors of CYP3A.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "64-75"], "DRUGB": ["itraconazole", "drug", "81-92"]}
{"ID": "DDI-DrugBank.d48.s11.p10", "TEXT1": "H2 Blockers/@DRUG$: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce @DRUG$ exposure.", "LBL": "0", "DRUGA": ["Proton Pump Inhibitors", "group", "12-33"], "DRUGB": ["dasatinib", "drug", "177-185"]}
{"ID": "DDI-DrugBank.d219.s23.p7", "TEXT1": "Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (@DRUG$ capsules and tablets) results in reduced protein binding of @DRUG$, but there was no change in the clearance of free warfarin.", "LBL": "0", "DRUGA": ["etodolac", "drug", "110-117"], "DRUGB": ["warfarin", "drug", "179-186"]}
{"ID": "DDI-DrugBank.d565.s18.p0", "TEXT1": "Administration of @DRUG$ with @DRUG$ in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.", "LBL": "DDI-mechanism", "DRUGA": ["diltiazem hydrochloride", "drug", "18-40"], "DRUGB": ["digoxin", "drug", "47-53"]}
{"ID": "DDI-DrugBank.d46.s3.p0", "TEXT1": "- @DRUG$: (Oral agents and @DRUG$) Dosage adjustment of the antidiabetic drug may be required", "LBL": "0", "DRUGA": ["Antidiabetic drugs", "group", "2-19"], "DRUGB": ["insulin", "drug", "39-45"]}
{"ID": "DDI-DrugBank.d202.s16.p14", "TEXT1": "Therefore, co-administration of tricyclic antidepressants with other drugs that are metabolized by this isoenzyme, including other @DRUG$, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (eg, propafenone, flecainide, and encainide), or that inhibit this enzyme (eg, @DRUG$), should be approached with caution.", "LBL": "0", "DRUGA": ["antidepressants", "group", "131-145"], "DRUGB": ["quinidine", "drug", "286-294"]}
{"ID": "DDI-DrugBank.d131.s9.p3", "TEXT1": "Data from in vitro studies of alprazolam suggest a possible drug interaction with @DRUG$ for the following: @DRUG$ and paroxetine.", "LBL": "DDI-int", "DRUGA": ["alprazolam", "drug", "82-91"], "DRUGB": ["sertraline", "drug", "112-121"]}
{"ID": "DDI-DrugBank.d521.s4.p9", "TEXT1": "- a monoamine oxidase inhibitor (@DRUG$) such as isocarboxazid (Marplan), @DRUG$ (Parnate), or phenelzine (Nardil);", "LBL": "0", "DRUGA": ["MAOI", "group", "33-36"], "DRUGB": ["tranylcypromine", "drug", "72-86"]}
{"ID": "DDI-DrugBank.d64.s93.p2", "TEXT1": "Drug/Laboratory Test Interferences: Dicumarol and @DRUG$, including @DRUG$, or their metabolites may color alkaline urine red-orange, which may interfere with spectrophotometrically determined urinary laboratory tests.", "LBL": "0", "DRUGA": ["indanedione anticoagulants", "group", "50-75"], "DRUGB": ["anisindione", "drug", "88-98"]}
{"ID": "DDI-DrugBank.d533.s7.p34", "TEXT1": "Co-administration of aliskiren did not significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, @DRUG$, @DRUG$, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.", "LBL": "0", "DRUGA": ["amlodipine", "drug", "116-125"], "DRUGB": ["metformin", "drug", "128-136"]}
{"ID": "DDI-DrugBank.d179.s3.p35", "TEXT1": "- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., @DRUG$]) or", "LBL": "0", "DRUGA": ["stanozolol", "drug", "108-117"], "DRUGB": ["Winstrol", "brand", "126-133"]}
{"ID": "DDI-MedLine.d30.s7.p0", "TEXT1": "In both species, @DRUG$, but not @DRUG$, antagonized the rate-decreasing effects of morphine on FI and FR responding.", "LBL": "0", "DRUGA": ["(-)-NANM", "drug_n", "17-24"], "DRUGB": ["(+)-NANM", "drug_n", "35-42"]}
{"ID": "DDI-DrugBank.d196.s3.p2", "TEXT1": "In patients with chronic hepatitis C treated with @DRUG$ in combination with COPEGUS, PEGASYS treatment did not affect @DRUG$ distribution or clearance.", "LBL": "0", "DRUGA": ["PEGASYS", "brand", "50-56"], "DRUGB": ["ribavirin", "drug", "120-128"]}
{"ID": "DDI-DrugBank.d484.s0.p672", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), @DRUG$ (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, @DRUG$, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["clofibrate", "drug", "282-291"], "DRUGB": ["Fortovase", "brand", "407-415"]}
{"ID": "DDI-DrugBank.d388.s5.p7", "TEXT1": "No significant interactions with digoxin, @DRUG$, hydralazine, @DRUG$, oral contraceptives, tolbutamide, or warfarin have been observed.", "LBL": "0", "DRUGA": ["hydrochlorothiazide", "drug", "42-60"], "DRUGB": ["sulfinpyrazone", "drug", "76-89"]}
{"ID": "DDI-DrugBank.d64.s87.p555", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;@DRUG$;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;@DRUG$;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["cimetidine", "drug", "253-262"], "DRUGB": ["methylphenidate", "drug", "544-558"]}
{"ID": "DDI-DrugBank.d440.s4.p2", "TEXT1": "Of over 3500 patients enrolled in the Ibandronate osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily @DRUG$ and @DRUG$).", "LBL": "0", "DRUGA": ["H2 blockers", "group", "136-146"], "DRUGB": ["PPIs", "group", "152-155"]}
{"ID": "DDI-DrugBank.d353.s12.p8", "TEXT1": "Vitamin A and oral retinoids: Concomitant administration of @DRUG$ and/or other oral retinoids with @DRUG$ must be avoided because of the risk of hypervitaminosis A.", "LBL": "DDI-advise", "DRUGA": ["vitamin A", "group", "60-68"], "DRUGB": ["acitretin", "drug", "103-111"]}
{"ID": "DDI-DrugBank.d3.s16.p0", "TEXT1": "The concurrent use of @DRUG$ with @DRUG$ has not been formally studied.", "LBL": "0", "DRUGA": ["TORADOL", "brand", "22-28"], "DRUGB": ["muscle relaxants", "group", "35-50"]}
{"ID": "DDI-DrugBank.d568.s9.p6", "TEXT1": "Digoxin - In subjects who had received 21 days of 40 mg/day racemic @DRUG$, combined administration of citalopram and @DRUG$ (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.", "LBL": "0", "DRUGA": ["citalopram", "drug", "68-77"], "DRUGB": ["digoxin", "drug", "122-128"]}
{"ID": "DDI-DrugBank.d179.s21.p50", "TEXT1": "- Phenothiazines (acetophenazine [e.g., @DRUG$], chlorpromazine [e.g., Thorazine], fluphenazine [e.g., @DRUG$], mesoridazine [e.g., Serentil], perphenazine [e.g., Trilafon], prochlorperazine [e.g., Compazine], promazine [e.g., Sparine], promethazine [e.g., Phenergan], thioridazine [e.g., Mellaril], trifluoperazine [e.g., Stelazine], triflupromazine [e.g., Vesprin], trimeprazine [e.g., Temaril]) or", "LBL": "0", "DRUGA": ["Tindal", "brand", "40-45"], "DRUGB": ["Prolixin", "brand", "103-110"]}
{"ID": "DDI-DrugBank.d45.s8.p6", "TEXT1": "Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including @DRUG$, antibiotics (metronidazole or @DRUG$) and aminosalicylates.", "LBL": "0", "DRUGA": ["corticosteroids", "group", "136-150"], "DRUGB": ["ciprofloxacin", "drug", "183-195"]}
{"ID": "DDI-DrugBank.d316.s6.p0", "TEXT1": "The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of @DRUG$ with @DRUG$ resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of felodipine.", "LBL": "0", "DRUGA": ["felodipine", "drug", "130-139"], "DRUGB": ["itraconazole", "drug", "146-157"]}
{"ID": "DDI-DrugBank.d334.s10.p1", "TEXT1": "Other Agents: @DRUG$ has been used concomitantly with nitrates and/or @DRUG$ without evidence of clinically significant adverse interactions.", "LBL": "0", "DRUGA": ["PRINIVIL", "brand", "14-21"], "DRUGB": ["digoxin", "drug", "72-78"]}
{"ID": "DDI-DrugBank.d45.s8.p9", "TEXT1": "Serum infliximab concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including corticosteroids, antibiotics (@DRUG$ or @DRUG$) and aminosalicylates.", "LBL": "0", "DRUGA": ["metronidazole", "drug", "166-178"], "DRUGB": ["ciprofloxacin", "drug", "183-195"]}
{"ID": "DDI-DrugBank.d64.s87.p174", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;@DRUG$;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;@DRUG$;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["aminosalicylic acid", "drug", "136-154"], "DRUGB": ["ethacrynic acid", "drug", "394-408"]}
{"ID": "DDI-DrugBank.d484.s0.p691", "TEXT1": "Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (@DRUG$), cyclosporine (@DRUG$, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.", "LBL": "0", "DRUGA": ["Atromid-S", "brand", "294-302"], "DRUGB": ["Neoral", "brand", "320-325"]}
{"ID": "DDI-DrugBank.d333.s7.p62", "TEXT1": "Pharmacodynamic Interactions: The CNS-depressant action of the benzodiazepine class of drugs may be potentiated by alcohol, narcotics, barbiturates, nonbarbiturate hypnotics, antianxiety agents, the phenothiazines, thioxanthene and @DRUG$, monoamine oxidase inhibitors and the tricyclic antidepressants, and by other @DRUG$.", "LBL": "0", "DRUGA": ["butyrophenone classes of antipsychotic agents", "group", "232-276"], "DRUGB": ["anticonvulsant drugs", "group", "356-375"]}
{"ID": "DDI-DrugBank.d419.s2.p2", "TEXT1": "In controlled clinical trials of AUGMENTIN XR, 22 patients received concomitant @DRUG$ and @DRUG$.", "LBL": "0", "DRUGA": ["allopurinol", "drug", "80-90"], "DRUGB": ["AUGMENTIN XR", "brand", "96-107"]}
{"ID": "DDI-DrugBank.d64.s87.p795", "TEXT1": "Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;@DRUG$;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;@DRUG$;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.", "LBL": "0", "DRUGA": ["diflunisal", "drug", "341-350"], "DRUGB": ["monoamine oxidase inhibitors", "group", "585-612"]}
{"ID": "DDI-DrugBank.d260.s0.p27", "TEXT1": "Probenecid : @DRUG$ is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., acetaminophen, acyclovir, angiotensin-converting enzyme inhibitors, aminosalicylic acid, barbiturates, benzodiazepines, bumetanide, clofibrate, methotrexate, famotidine, furosemide, nonsteroidal anti-inflammatory agents, @DRUG$, and zidovudine).", "LBL": "DDI-mechanism", "DRUGA": ["Probenecid", "drug", "13-22"], "DRUGB": ["theophylline", "drug", "334-345"]}
{"ID": "DDI-DrugBank.d94.s11.p170", "TEXT1": "Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, @DRUG$, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, @DRUG$, warfarin(5) , ziprasidone, and zonisamide.", "LBL": "0", "DRUGA": ["amitriptyline", "drug", "184-196"], "DRUGB": ["valproate", "drug", "692-700"]}
{"ID": "DDI-DrugBank.d542.s0.p1", "TEXT1": "Interactions for @DRUG$ (Niacin): @DRUG$ Therapy: Nicotinic acid may potentiate the effects of ganglionic blocking agents and vasoactive drugs resulting in postural hypotension.", "LBL": "0", "DRUGA": ["Vitamin B3", "drug", "17-26"], "DRUGB": ["Antihypertensive", "group", "38-53"]}
{"ID": "DDI-MedLine.d118.s2.p7", "TEXT1": "Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of @DRUG$ does not appear to overlap to any great extent with that associated with @DRUG$ or tacrolimus.", "LBL": "0", "DRUGA": ["sirolimus", "drug", "148-156"], "DRUGB": ["cyclosporine", "drug", "231-242"]}
{"ID": "DDI-DrugBank.d411.s10.p2", "TEXT1": "@DRUG$ (interferon, interleukin): @DRUG$ have been reported to induce both hyperthyroidism and hypothyroidism.", "LBL": "0", "DRUGA": ["Cytokines", "group", "0-8"], "DRUGB": ["Cytokines", "group", "37-45"]}
